{"ticker": {"uuid": "cddcb5eb-dfb3-406c-83b5-793c002cbf3a", "symbol": "MIRM", "name": "Mirum Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Mirum Pharmaceuticals (MIRM) Stock Looks Fully Valued On Current Sales Expectations", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-23T06:38:16+00:00", "published_display": "23 Jul 2026 06:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why (MIRM) Price Action Is Critical for Tactical Trading", "summary": "This article analyzes Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) for tactical trading, highlighting a mid-channel oscillation pattern and a strong risk-reward short setup. It details institutional trading strategies, including long, breakout, and short positions, alongside multi-t", "url": "https://news.stocktradersdaily.com/news_release/17/Why_MIRM_Price_Action_Is_Critical_for_Tactical_Trading_072026025202_1784530322.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-20T02:41:41", "published_display": "20 Jul 2026 02:41", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MIRM5806400 Bond Risk Profile", "summary": "This article provides an overview of the MIRM5806400 bond issued by Mirum Pharmaceuticals, Inc. The bond has a 4.0% coupon and matures on May 1, 2029. It outlines key metrics for risk analysis, including security level, inflation protection, and issuer rating to help evaluate the", "url": "https://www.tradingview.com/symbols/FINRA-MIRM5806400/profile-risks/", "source_name": "TradingView", "published_at": "2026-07-16T12:12:46", "published_display": "16 Jul 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US604749AB7 Bond Profile \u2014 Key Metrics", "summary": "This article provides key metrics for the Mirum Pharmaceuticals, Inc. 4.0% 01-MAY-2029 bond (US604749AB7). It details the issuer, issue and maturity dates, outstanding amount, face value, and coupon rate. Mirum Pharmaceuticals, Inc. is described as a biopharmaceutical company foc", "url": "https://www.tradingview.com/symbols/FWB-US604749AB7/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-16T04:10:39", "published_display": "16 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/mirum-pharmaceuticals-reports-inducement-grants-200100841.html", "source_name": "Business Wire", "published_at": "2026-07-13T20:01:00+00:00", "published_display": "13 Jul 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Mirum Pharma staff get stock options at $122.13 a share", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPaVJPeV8xcUF1cWJaNjU4cWtGQlNEWHpoRXdJNUhWNkJwTHJUdDB5SGZxX3dhRXdUVElCZ3JnV0ZfbU1FRTV3Ml94cEVleG02VkNEaE9KdDdTeWUxYXZLYS1EYVlDNm1KRk9NUWo2THdZMklXWEpGcUlzbk9wcFpRdFpRZHJiZGEyNWEzQ3FwRWtTZ2tKNDY4MS0tSkNna25abmpNa2wydUhNYnJ1dGROT2tiOWMzWEduQVJXSHd6a08?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Form 4 Mirum Pharmaceuticals Inc For: 8 July By Investing.com", "summary": "This article reports on a Form 4 filing for Mirum Pharmaceuticals Inc related to activity on July 8th, as published by Investing.com. It is a brief announcement without further details, typical of stock market updates. The article also provides standard Investing.com market data,", "url": "https://ng.investing.com/news/stock-market-news/form-4-mirum-pharmaceuticals-inc-for-8-july-93CH-2591907", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T19:09:46", "published_display": "09 Jul 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals Insider Sold Shares Worth $611,273, According to a Recent SEC Filing", "summary": "An insider at Mirum Pharmaceuticals sold shares valued at $611,273 according to a recent SEC filing. This transaction indicates a significant insider sale, which is often monitored by investors for insights into a company's financial health and future prospects. Further details o", "url": "https://www.moomoo.com/news/post/72670447/mirum-pharmaceuticals-insider-sold-shares-worth-611273-according-to-a?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-09T18:10:12", "published_display": "09 Jul 2026 18:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals (MIRM) CEO sells 20,000 shares after exercising options", "summary": "Mirum Pharmaceuticals CEO Christopher Peetz exercised options for 20,000 shares and subsequently sold all 20,000 common shares in open-market transactions on July 6, 2026, as part of a pre-planned Rule 10b5-1 plan. The sale, valued at approximately $2.45 million, occurred at pric", "url": "https://www.stocktitan.net/sec-filings/MIRM/form-4-mirum-pharmaceuticals-inc-insider-trading-activity-ad7f0e0c8f51.html", "source_name": "Stock Titan", "published_at": "2026-07-09T06:39:15", "published_display": "09 Jul 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals Insider Sold Shares Worth $2,445,382, According to a Recent SEC Filing", "summary": "An insider at Mirum Pharmaceuticals recently sold shares totaling $2,445,382, as disclosed in a recent SEC filing. This transaction indicates a significant insider sell-off. Further details would be needed to understand the context and potential implications of this sale.", "url": "https://www.moomoo.com/news/post/72670629/mirum-pharmaceuticals-insider-sold-shares-worth-2445382-according-to-a?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-09T06:09:56", "published_display": "09 Jul 2026 06:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell Alert: Eric Bjerkholt Sells 5,000 Shares of Mirum P", "summary": "Eric Bjerkholt, CFO of Mirum Pharmaceuticals Inc (MIRM), sold 5,000 shares on July 6, 2026, reducing his holdings to 42,181 shares. This sale is part of a trend of 40 insider sells against 1 insider buy over the past year for the company. The stock, trading at $122.25, is conside", "url": "https://www.gurufocus.com/news/8950622/insider-sell-alert-eric-bjerkholt-sells-5000-shares-of-mirum-pharmaceuticals-inc-mirm", "source_name": "GuruFocus", "published_at": "2026-07-09T01:11:18", "published_display": "09 Jul 2026 01:11", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals CEO Christopher Peetz sells $2.4 million in stock", "summary": "Mirum Pharmaceuticals CEO Christopher Peetz sold 20,000 shares of the company's common stock for approximately $2.4 million on July 6, 2026, following the exercise of employee stock options. The sales occurred after a 155% surge in MIRM stock over the past year, with an Investing", "url": "https://www.investing.com/news/insider-trading-news/mirum-pharmaceuticals-ceo-christopher-peetz-sells-24-million-in-stock-93CH-4782610", "source_name": "Investing.com", "published_at": "2026-07-08T21:11:18", "published_display": "08 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals (MIRM) CFO sells 5,000 shares under 10b5-1 plan", "summary": "Mirum Pharmaceuticals' Chief Financial Officer, Eric Bjerkholt, sold 5,000 shares of common stock on July 6, 2026, through open-market transactions under a pre-arranged Rule 10b5-1 plan. The sales occurred at prices ranging from approximately $121.13 to $124.94 per share. Followi", "url": "https://www.stocktitan.net/sec-filings/MIRM/form-4-mirum-pharmaceuticals-inc-insider-trading-activity-083fcefccdb0.html", "source_name": "Stock Titan", "published_at": "2026-07-08T21:11:18", "published_display": "08 Jul 2026 21:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts Mirum Pharmaceuticals Price Target to $148 From $142, Maintains Outperform Rating", "summary": "RBC Capital has increased its price target for Mirum Pharmaceuticals (MIRM) to $148 from $142, while maintaining an Outperform rating on the stock. This adjustment reflects continued analyst confidence in the biopharmaceutical company, which focuses on treatments for rare liver d", "url": "https://www.marketscreener.com/news/rbc-capital-adjusts-mirum-pharmaceuticals-price-target-to-148-from-142-maintains-outperform-ratin-ce7f5ed8d981f425", "source_name": "marketscreener.com", "published_at": "2026-07-07T12:41:55", "published_display": "07 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eric Bjerkholt reports sale of 5,000 MIRM shares (MIRM)", "summary": "Eric Bjerkholt has reported the sale of 5,000 shares of Mirum Pharmaceuticals (MIRM) common stock on June 8, 2026, with a reported value of $469,073.00. This transaction was disclosed via a Form 144 filing, which is a routine notice for proposed sales of restricted securities. Th", "url": "https://www.stocktitan.net/sec-filings/MIRM/144-mirum-pharmaceuticals-inc-sec-filing-d1f17652102b.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:39:57", "published_display": "06 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Christopher Peetz plans 20,000-share sale (NASDAQ: MIRM)", "summary": "Christopher Peetz has filed a Form 144 indicating a proposed sale of 20,000 shares of Mirum Pharmaceuticals (NASDAQ: MIRM) common stock, which will be executed via a stock option exercise on July 6, 2026. The filing also reports a previous sale of 30,000 shares on June 1, 2026. T", "url": "https://www.stocktitan.net/sec-filings/MIRM/144-mirum-pharmaceuticals-inc-sec-filing-f6ee52aa9edf.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:39:57", "published_display": "06 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Priority Review For Zilurgisertib Could Be A Game Changer For Mirum Pharmaceuticals (MIRM)", "summary": "Mirum Pharmaceuticals (MIRM) has received FDA priority review for zilurgisertib, a drug for fibrodysplasia ossificans progressiva, with a decision expected in late September 2026. This accelerated review and positive phase II results could significantly expand Mirum's rare diseas", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/fda-priority-review-for-zilurgisertib-could-be-a-game-change", "source_name": "Simply Wall Street", "published_at": "2026-07-06T18:10:58", "published_display": "06 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Mirum Pharmaceuticals, Inc. \u2013 NASDAQ:MIRM", "summary": "This article provides financial information for Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) on TradingView. It focuses on the company's enterprise value to EBIT forward metric. The content highlights the stock's market data and available financial tools on the platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-MIRM/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T05:39:57", "published_display": "05 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "J.P. Morgan Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $125", "summary": "J.P. Morgan has reiterated its Buy rating for Mirum Pharmaceuticals (MIRM.US) and increased its price target to $125. This indicates a continued positive outlook from the financial institution regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72406219/jp-morgan-maintains-mirum-pharmaceuticals-mirmus-with-buy-rating-raises", "source_name": "Moomoo", "published_at": "2026-07-03T16:39:13", "published_display": "03 Jul 2026 16:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals SVP sells $326,520 in common stock", "summary": "Jolanda Howe, Senior Vice President at Mirum Pharmaceuticals, sold 2,721 shares of the company's common stock for $326,520, with shares trading at $120.0 each. This sale occurred while the stock was near its 52-week high after a significant 156% gain over the past year, and was e", "url": "https://www.investing.com/news/insider-trading-news/mirum-pharmaceuticals-svp-sells-326520-in-common-stock-93CH-4774535", "source_name": "Investing.com", "published_at": "2026-07-03T05:09:47", "published_display": "03 Jul 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRM - Mirum Pharmaceuticals Inc Latest SEC Filings", "summary": "This article provides the latest SEC filing information for Mirum Pharmaceuticals Inc. (MIRM), offering a comprehensive overview of its financial performance, key valuation metrics, and stock market statistics. It details various financial ratios, insider and institutional owners", "url": "https://finviz.com/stock?t=MIRM&ty=lf&ta=0&p=w&page=17", "source_name": "Finviz", "published_at": "2026-07-03T03:40:42", "published_display": "03 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Jolanda Howe Sells Shares of Mirum Pharmaceuticals Inc (MIRM)", "summary": "Jolanda Howe, Senior Vice President, Global Controller at Mirum Pharmaceuticals Inc, sold 2,721 shares of the company on July 1, 2026, reducing her holdings to 3,114 shares. This transaction is part of a pattern of 39 insider sells against only 1 insider buy for MIRM over the las", "url": "https://www.gurufocus.com/news/8943939/insider-sell-jolanda-howe-sells-shares-of-mirum-pharmaceuticals-inc-mirm", "source_name": "GuruFocus", "published_at": "2026-07-03T00:40:42", "published_display": "03 Jul 2026 00:40", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals (MIRM) SVP Howe sells 2,721 shares under 10b5-1 plan", "summary": "Mirum Pharmaceuticals' SVP and global controller, Jolanda Howe, sold 2,721 shares of common stock at $120.00 per share in an open-market transaction. This sale, totaling $326,520, was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 18, 2026. Following the ", "url": "https://www.stocktitan.net/sec-filings/MIRM/form-4-mirum-pharmaceuticals-inc-insider-trading-activity-e4246a0bc953.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:40:42", "published_display": "02 Jul 2026 21:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals (MIRM) Rallies On Trial News As Its Valuation Story Gets Harder To Ignore", "summary": "Mirum Pharmaceuticals (MIRM) shares rallied 5.5% after positive phase II data and an FDA priority review for zilurgisertib, impacting its market value which now stands at US$7.3 billion. The stock has seen a strong uplift with a 25.05% return in 30 days and 54.30% year-to-date, p", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-rallies-on-trial-news-as-its-valu", "source_name": "Simply Wall Street", "published_at": "2026-07-02T17:40:42", "published_display": "02 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals stock hits all-time high at 125.41 USD", "summary": "Mirum Pharmaceuticals' stock reached an all-time high of $125.41, bringing its market capitalization to $7.6 billion, despite an InvestingPro analysis suggesting it might be overvalued. The company has seen a 147.06% increase over the last year and strong revenue growth of 50%. R", "url": "https://www.investing.com/news/company-news/mirum-pharmaceuticals-stock-hits-alltime-high-at-12541-usd-93CH-4773378", "source_name": "Investing.com", "published_at": "2026-07-02T14:40:42", "published_display": "02 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals stock hits all-time high at 125.41 USD By Investing.com", "summary": "Mirum Pharmaceuticals' stock reached an all-time high of $125.41, marking a 147.06% increase over the past year and bringing its market capitalization to $7.6 billion. Despite this, InvestingPro analysis suggests the stock might be overvalued relative to its Fair Value. The compa", "url": "https://ca.investing.com/news/stock-market-news/mirum-pharmaceuticals-stock-hits-alltime-high-at-12541-usd-93CH-4718499", "source_name": "Investing.com Canada", "published_at": "2026-07-02T14:39:57", "published_display": "02 Jul 2026 14:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Mirum Pharmaceuticals (MIRM) Could Change Following Priority FDA Review Of FOP Drug Zilurgisertib", "summary": "Mirum Pharmaceuticals recently reported positive phase II results for zilurgisertib in fibrodysplasia ossificans progressiva (FOP) and received FDA priority review. This development could reshape the investment narrative for Mirum, moving it beyond its reliance on Livmarli and st", "url": "https://sg.finance.yahoo.com/news/bull-case-mirum-pharmaceuticals-mirm-091455002.html", "source_name": "Market source", "published_at": "2026-07-02T09:14:57", "published_display": "02 Jul 2026 09:14", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 MIRUM PHARMACEUTICALS For: 1 July By Investing.com", "summary": "This article from Investing.com reports the filing of Form 144 for MIRUM PHARMACEUTICALS on July 1st. It provides the headline and mentions the stock symbol MIRM, along with a slight percentage increase. The article is very short and largely surrounded by extensive financial mark", "url": "https://ca.investing.com/news/stock-market-news/form-144-mirum-pharmaceuticals-for-1-july-93CH-4717208", "source_name": "Investing.com Canada", "published_at": "2026-07-02T03:39:02", "published_display": "02 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "2,721 performance shares proposed; Jolanda Howe sold 2,594 (MIRM)", "summary": "A Form 144 filing by Morgan Stanley Smith Barney LLC Executive Financial Services discloses a proposed resale of 2,721 performance shares of Mirum Pharmaceuticals, Inc. (MIRM) dated March 15, 2026. The filing also reports that Jolanda Marie Howe previously sold 2,594 common share", "url": "https://www.stocktitan.net/sec-filings/MIRM/144-mirum-pharmaceuticals-inc-sec-filing-47c6dfd85891.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:39:01", "published_display": "01 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Mirum Pharmaceuticals, Inc. \u2013 NASDAQ:MIRM", "summary": "This page from TradingView provides financial information for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), specifically focusing on its forward price-to-sales ratio. The content appears to be a financial data point within a larger platform, showing the company's value for a specifi", "url": "https://www.tradingview.com/symbols/NASDAQ-MIRM/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T19:44:25", "published_display": "01 Jul 2026 19:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals Stock Surges 25%, With A 9-Day Winning Spree", "summary": "Mirum Pharmaceuticals (MIRM) recently experienced a 9-day winning streak, with its stock surging 25% and its market cap increasing by about $1.4 billion to $7.3 billion. While the company demonstrates strong operating performance, its current valuation is considered very high, ma", "url": "https://www.trefis.com/stock/mirm/articles/604921/mirum-pharmaceuticals-stock-surges-25-with-a-9-day-winning-spree/2026-06-29", "source_name": "Trefis", "published_at": "2026-06-29T14:40:53", "published_display": "29 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Mirum Pharmaceuticals, Inc. \u2013 NASDAQ:MIRM", "summary": "This article provides financial information for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), focusing on its forward price-to-book ratio. It appears to be a stub or an entry from a financial data platform, indicating the company's financials, news, community, technicals, and foreca", "url": "https://www.tradingview.com/symbols/NASDAQ-MIRM/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T14:40:53", "published_display": "29 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOb1FGX19JSm5TLTFnTUV6eHF4Q0tDZ1pWUzRhM0tNeGtLWTJRTXpQQVFSMWNjWERlNzk0VUFEU2N0Slgwb21pcTM3dENzVm9iTVUtaWVEQjZxNlJnR3dEX2hXMnM3V3I4WjVDdXJ3ams0VWxDX2lzTlRZd3U1dVJpXzA0VlVwa19UOWd3QWlsbTRQUHdCNkxYOGhwc2RfY3dfVHJQVjlvUG0?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "9-Day Rally Sends Mirum Pharmaceuticals Stock Up 25%", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOVk52elB6dHBfcnFxd3loTDdQZU12NjhfWXU0QTFKX1NDN19xMDhqRFNpSlFETDlVZ29QV3gyM29aZDFDQ0hWODJWNHk0NkYtb2RrTFdoV0hPTHo5eDVNa2xtWG83eDNpcjY1M0VXZXhXYW8wUHhjZFRfZUFrRnZGM2Q5VTRmUXVXTlhPSVZuM21rZUY5eWg3eDRZRGFiRmJiam1UY213RzhYVG0zaHdub3lDckRIV1lqYjZlMjE5cw?oc=5", "source_name": "Trefis", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals Stock Surges 18%, With A 8-Day Winning Spree", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNT3VTeTRnMjRKQlc0S3FMMm5RcjJLaGFocFpVSU1WYjNtOEdld3l1ZTNEczRzN3lqY0FKMkVFN1JqOUFBNFNFWmgzcFcyc2p6clJZdVNLaVUyM3ZMeVQ3MWI1RC1nWnNMQWJsUjFGSG5hM2ZJb2JJcGY5OW1TRTlKUElucmtNRlU4WDRXbUxxSU5Cb09DWnFLMnRfZVFWTXY1NUdOQURrYjhMNW9yaFVLOHI3UWdEaldCRmFpamxicnVLaUE?oc=5", "source_name": "Trefis", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPS0thTmZBX2I1YVJ4WGx5TGxscC0zaHZHR3ZOeW5QUlduZU5Wd0pjelUxQVlZZ2FhcEgxRnhOQk9SWGFmMVBOUnZZdjM2NlJWbTFBNUN3UWhLTm5Vb3hJd3NaaEV1bURNam9CUDVSbG52TTNpRVliMzR6VHZRbVFqY1ladktiLXZhcjJVUnVCR2VUTzAzTXhmUUdlSUpJV04wUXc?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQbi1RTUhFQWZaaWJBcHlxbFpIcDlLdkEwRWpnRzVVbTY5Q2JxNHRKZTV4S0U4b0dabzR6d1BMRXhfSnNLWjVWMXU5UVc0cXpjVWozdVU4aDlxZnpjWlRaSGtNSmVBOXVMai1CNFU0N1Z2bi1uRVhLdmtxREEzeURZLXFYTWpZTlhhWXFLcGRoSVJ6VUFSM2RfeHhGV21BVXl4SlE?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum\u2019s VISTAS Success And What It Could Mean For MIRM Shareholders", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxQMzF6ZHJxVlRLWUNFVE8xaEZqdlNHRlFkZjVsdkRBdWk1TEFoT2Qzd3NaRHVaOGxDMkhQTFFoS3JRYkdNOXE4SkxOVU94NjhUOXZkbm9paThPSmg4ck9ueXhJczkzYjlwWU9Nd0R2UF85cUZwV3dSWUU2MHl2a2dXY1prNmxMNXVHTEwwTnpVR05SLWc3bUlDUUpyMVc5bnNaMy11LVAwTkxERE9GdHFzT2ZoQ1ZXMm83RXhRMjVDbHdkNGd1YlJPc0ZkM28wd1FLYlpBV01teDItclRBcWw0eXBxMWx5YXo2b21n0gHwAUFVX3lxTFByNjU0M01mQXVwNWtPQ1p4MHlSOFY5YkNVZUtVMkxHWWZfMjhWYWluTDI5dERabEprMlY5WTdVRGoyZy1ackRSZVQyYldJNGRYVlZnZDkxV3RZOXhYeGtxdTYtTU1uN1BqMTljaWlEUlVnTnF5NmNmNVlveXJuVHJKTEpuemhXQnk2V3JJdzNRbncyblBWeGd5RXdoQkFoS1hHN3FZd3dPcnZNUjY0MTRGX2JHa3h1Q0pvNVN2RlNqV005bEh1STBjb1dkXzZxNU1BTWgwWllEOTMwUkplMlFLNk1lSk01T3dzc0k1WVliMw?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Mirum Pharmaceuticals: A Rare Disease Platform Becoming Bigger Than Its First Franchise", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQTDYteEV5ZDUwTHNDUk1GQkdENzdDNFVGLXdncDlCUUxGVXFFUGJzQS1mWjY4T2dRMTRPM0l5MEdKZHFCYkZvVkV2d1A2aEFpUlFobkhnMHB6TGxUZ19kV0lYZFlvakNGOFR3c3I0bTE5LTNjbUtkSWQ2SjItMXBucnNBSThCa24tanZ6aVRYd3lSLTFOcGZlX19ST1Q5TkVmdFh2ejA1NWhjbkM0UHFjbVA1czZNc28xZGN0aV9DZzZ4WWFyT0RaRGxxSQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals\u2019 $600M notes with 2029 exchange and stock hedge unwinds", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPc0dxLTFwaWFabHZHdzhYNWpUTEstdVVnUGR2RzBxU1FpWk5yaTBOVlRTa0JUWHpFaFEtc0lCY0NvUzFiQ05mLXpzMFNGOVd4ZHczRzNlRVNZQnZlTzl2cXZYR1FZVGdfekJfd01qX01BeVdZNV95c2FPbUppaWE3dGZKRmZYRWJpeEVjVkJSQ3FDNnpRaGsxZDR6cmU5QTNDcDNjVXRRNDVxdEx2dWV2ZVhfOG5MaGhqQnR4UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Mirum Pharmaceuticals (MIRM) Posts Huge US$790 Million Loss Challenging Bullish Profitability Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q1 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPQkJLYTFBQkc1Ni1kaGFnREhRRTlhTlJ1OWJYS191cWpXbVU1elg3Yi01V1hkUDFZR01Xc2xzRHJBZmh3OXFVQnRmY3VnM0dZX2t4bEtwTXJVSzV6T0pnY1FtcDdJNm9EMllDYW5LUkZPLVpWY3ZsZFlmQ3VDWFFYbV9oY3RpdnJ0alhreGZqd2ZvdFVz?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQa3lXVkJkS3pjeV9tLVZ2aWlSN1FjVmxiVEFjZUtnWVdURE5Fc1NzRDhzbmRtRnBOQkFUQnEwSTc5UmE3M1RabXg1eWlHUVlPdkJ5YXZxanFvVzJ1SkktUW5UM1RJU0xTZEVzNGRtdkVRNnlTOWo2bzVJWXFmYkNBc0tOXzJVNm84eE91ZUZHVkZYME1aUm93RnFYY0psYWhyb29vcDVWVQ?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BlackRock (NASDAQ: MIRM) Holds 3.47M Shares, 5.7% Stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQcnJkUDl4QjE0MjVJLXNpZVJ2Mlp3bTllQ05RVnNBM0lib0VsOVZBREVmVWNWOXdTSW1xb1ZfaFVZak5BZTFrRTJrdWtvVFRrRlFheU4zaWNNZFF6ZC13WFd0aTIxMEpmbW10M2NmajA0d1E4WXF6dFFGdjV3OUI0Smc4Q3RFRzJScDZGQllZTHYwNXpndDB3cWpwOHhaLTNFd1Q2NTdYcTFubEdXem1od3ZCSWZlSlkxMHQ0blRCZlZJRlg0eDhGdjFvQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Mirum Pharmaceuticals\u2019 Stock Surged Over 120% in One Year and May Continue to Climb", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPZlBsbUJla2FvQ0F0V0wySHNwSkNpYlgwWlZlSDdrMFgwWUc3ajdFMWFRWmNFbkN2cE1QUjlSOXVDR1Y1cktnS25PdGxTTEoxb2RKcUpNLUFzSTRJSzZFVXI1dk9aa05TdFlzVXUzMWV3dHF5VlljSGxWUTA5N3dHTnViY3NxMFBsLS1kRmxoejJNQUVZbmZIT3ZJakpvbE9sWndHNmVQd25FZkhnZHY2ZmxvZ0s?oc=5", "source_name": "NAI500", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After Its Strong Multi\u2011Year Share Price Run?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPejd3Y3J5eDdOMFVaRE42cFd2T3hHTmJZSVk2TFRNZXNreEp1T3BST3I1Z3Q5UUNDVkwwSk5HQzV6NndfY1Fsa25GQXgtNzM5QktmenNwd0xlYTlBWXIwa3RWZHB5aExJWTZfQnRISjQzNURTR0pSc09zVFFhbWs2bDl6anMyT2tNel84WHZpZ3JaVGNZNy1WSktqeDJxV19YTXFXUW0tOA?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals (MIRM) Moves 5.1% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQelZ0YW41dGZZUU43SmI2ZVdnRm5jeWJoQWNBd1VKd2dtRFpXNHE2SnNDMXJGeTZzU1hxVWlIUFd2UDRONUk0dS02dUt3cHpITzU2VC1nbHhOaXhPZDJVeENucGZBYUk0bUhjc0QySWhtSHgtZ2tWNXg5b1M5UHlzcklwemtGRGtzWXlJYkU0cFdRVjJ4aFdYVTNFT2pvQjBy?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After Its Strong Multi Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxOdUtfeVY4SU1KR1lPMXZnZFNhd2J6aTdraElHQTI1NkNKbmhMV0NEdlpvSGIwYXdhNGJTbExPOUtWS2Uwa253eFNFbDI4eXl6NEtvY2liZ2swZjlKZTBlZ2RGNHZHQ1JHZWNNZ2NQRF9IY1JZSm5yeXZURS1QdUU5ZG5MVXdldG8yQW1OUjJ4eWNIN3FoSmkxNFhhWklWS2RBY0J6cEU5ZW13R1hXUnA3d1M1cnNPWEotaHpBLTNqVHhIT3hZaHpsSFp4RFVLSGp2cTBPUXNmdE5sNFBydUJRZEQybV9SSjljMUxKTNIB8gFBVV95cUxPd2YyM21WM05WYWtBSHpkdnVlMENxemJyRktiRUJlTDB5ZXdLVk5sSm5lWURHd2RTZTZlTTlnODFuNFRCUnA0cXJ2X2tRSTU2UFpvRFFXd1RGQUxMZ3psdV9PUFBIMWhpQVUyc2VESTE5SExFR2JCNV9zbEdvQkxvTC1oOU9wNlYyRVIyMzFFTmQ0eDFob3F3a3pRY2xZdXgxaU0zUGsxMzczclhmSng5TFRTT1hRRzlWUUo2U28zWng1SmlPN1B2cm1WbkpSZnJ2NDFjeElWeE9meG9TVHNQZVkxY1pPT3pYMDFFQUVWbDI1Zw?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNMlVMWlBQTmZ4SzQ4TnNIQnVQQjI2QmJXblNuWnZxVndTekhGR0xWc2VaWFFoRFNhbm5MdTluTGFHcWFlUUxWMGdnS01TMmdfWW50SkNVUkcyNGZJcTZ0M2NPbkVUWWdkRjZWOXFWcy1lMnpUdUpPVDZKbkw3MVNrQllxaDg2cjRQM0N0NjFpM0d0YXMwQ1E0?oc=5", "source_name": "Finviz", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals Completes $268.6 Million Acquisition of Bluejay Therapeutics to Strengthen Rare Disease Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPblRuVUR0OUJER1RoSy1QN1hQSUxjaEJDVjB6NTNHb3JZcXBSQWhfUUpfREpEb1BSRDFXbl9Ib2ROV2l4aWlleXlVcjRBVUZLZGd4ZlprVGxwOEsxMWs4Wm16RjJlOGUyNDdwVlp1SEppUEJfM3JFWUNJMERsTThuZGp3ZjJmaEJyMjVhWmtHdzVSdi1vcUZSajdTcFlnZUFOSkJGeU9fR0dCVWhMWWZrcHFGcWVJcVQtUTR4VFRObndMLTNRRVg1VjhhRERCeHNpQXEwYS1ldw?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxNLWtpdThxLWgwdDZhUXl5S1BPbXlERU9jc1psaFZYT05qcVpzX1FaQThrS2x3SmtCLXJiV0R5dGVLeVRkMlhBTW9VcDl5ZVZFcWZFVkZoNlo0dkVHR24zUnVZSkZMT3F2RzhyZGxFXy03d2l4UEx2akdJQnlSZHd0aTJ2Z0p1VUV2LXFtTFQ3ZTdoTkRPS0tYS0U5LXZQTmdQV1ZKTXpXclRjWTl3MWtZT2wxamxvN3VaX0RCYWtUNkpFNmhBZ1lHSGtPWGR1VEZRQ2VaUEZBSUx6bkd5X3hjMWVURk9sYjF3WFo0TURqU3VEZ1FaRG9BX0ZFNmQ?oc=5", "source_name": "Business Wire", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Mirum Pharmaceuticals (MIRM) Stock Looks Fully Valued On Current Sales Expectations", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-23T06:38:16+00:00", "published_display": "23 Jul 2026 06:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why (MIRM) Price Action Is Critical for Tactical Trading", "summary": "This article analyzes Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) for tactical trading, highlighting a mid-channel oscillation pattern and a strong risk-reward short setup. It details institutional trading strategies, including long, breakout, and short positions, alongside multi-t", "url": "https://news.stocktradersdaily.com/news_release/17/Why_MIRM_Price_Action_Is_Critical_for_Tactical_Trading_072026025202_1784530322.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-20T02:41:41", "published_display": "20 Jul 2026 02:41", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRM5806400 Bond Risk Profile", "summary": "This article provides an overview of the MIRM5806400 bond issued by Mirum Pharmaceuticals, Inc. The bond has a 4.0% coupon and matures on May 1, 2029. It outlines key metrics for risk analysis, including security level, inflation protection, and issuer rating to help evaluate the", "url": "https://www.tradingview.com/symbols/FINRA-MIRM5806400/profile-risks/", "source_name": "TradingView", "published_at": "2026-07-16T12:12:46", "published_display": "16 Jul 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US604749AB7 Bond Profile \u2014 Key Metrics", "summary": "This article provides key metrics for the Mirum Pharmaceuticals, Inc. 4.0% 01-MAY-2029 bond (US604749AB7). It details the issuer, issue and maturity dates, outstanding amount, face value, and coupon rate. Mirum Pharmaceuticals, Inc. is described as a biopharmaceutical company foc", "url": "https://www.tradingview.com/symbols/FWB-US604749AB7/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-16T04:10:39", "published_display": "16 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/mirum-pharmaceuticals-reports-inducement-grants-200100841.html", "source_name": "Business Wire", "published_at": "2026-07-13T20:01:00+00:00", "published_display": "13 Jul 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Mirum Pharma staff get stock options at $122.13 a share", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPaVJPeV8xcUF1cWJaNjU4cWtGQlNEWHpoRXdJNUhWNkJwTHJUdDB5SGZxX3dhRXdUVElCZ3JnV0ZfbU1FRTV3Ml94cEVleG02VkNEaE9KdDdTeWUxYXZLYS1EYVlDNm1KRk9NUWo2THdZMklXWEpGcUlzbk9wcFpRdFpRZHJiZGEyNWEzQ3FwRWtTZ2tKNDY4MS0tSkNna25abmpNa2wydUhNYnJ1dGROT2tiOWMzWEduQVJXSHd6a08?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Mirum Pharmaceuticals Inc For: 8 July By Investing.com", "summary": "This article reports on a Form 4 filing for Mirum Pharmaceuticals Inc related to activity on July 8th, as published by Investing.com. It is a brief announcement without further details, typical of stock market updates. The article also provides standard Investing.com market data,", "url": "https://ng.investing.com/news/stock-market-news/form-4-mirum-pharmaceuticals-inc-for-8-july-93CH-2591907", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T19:09:46", "published_display": "09 Jul 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals Insider Sold Shares Worth $611,273, According to a Recent SEC Filing", "summary": "An insider at Mirum Pharmaceuticals sold shares valued at $611,273 according to a recent SEC filing. This transaction indicates a significant insider sale, which is often monitored by investors for insights into a company's financial health and future prospects. Further details o", "url": "https://www.moomoo.com/news/post/72670447/mirum-pharmaceuticals-insider-sold-shares-worth-611273-according-to-a?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-09T18:10:12", "published_display": "09 Jul 2026 18:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals (MIRM) CEO sells 20,000 shares after exercising options", "summary": "Mirum Pharmaceuticals CEO Christopher Peetz exercised options for 20,000 shares and subsequently sold all 20,000 common shares in open-market transactions on July 6, 2026, as part of a pre-planned Rule 10b5-1 plan. The sale, valued at approximately $2.45 million, occurred at pric", "url": "https://www.stocktitan.net/sec-filings/MIRM/form-4-mirum-pharmaceuticals-inc-insider-trading-activity-ad7f0e0c8f51.html", "source_name": "Stock Titan", "published_at": "2026-07-09T06:39:15", "published_display": "09 Jul 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals Insider Sold Shares Worth $2,445,382, According to a Recent SEC Filing", "summary": "An insider at Mirum Pharmaceuticals recently sold shares totaling $2,445,382, as disclosed in a recent SEC filing. This transaction indicates a significant insider sell-off. Further details would be needed to understand the context and potential implications of this sale.", "url": "https://www.moomoo.com/news/post/72670629/mirum-pharmaceuticals-insider-sold-shares-worth-2445382-according-to-a?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-09T06:09:56", "published_display": "09 Jul 2026 06:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell Alert: Eric Bjerkholt Sells 5,000 Shares of Mirum P", "summary": "Eric Bjerkholt, CFO of Mirum Pharmaceuticals Inc (MIRM), sold 5,000 shares on July 6, 2026, reducing his holdings to 42,181 shares. This sale is part of a trend of 40 insider sells against 1 insider buy over the past year for the company. The stock, trading at $122.25, is conside", "url": "https://www.gurufocus.com/news/8950622/insider-sell-alert-eric-bjerkholt-sells-5000-shares-of-mirum-pharmaceuticals-inc-mirm", "source_name": "GuruFocus", "published_at": "2026-07-09T01:11:18", "published_display": "09 Jul 2026 01:11", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals CEO Christopher Peetz sells $2.4 million in stock", "summary": "Mirum Pharmaceuticals CEO Christopher Peetz sold 20,000 shares of the company's common stock for approximately $2.4 million on July 6, 2026, following the exercise of employee stock options. The sales occurred after a 155% surge in MIRM stock over the past year, with an Investing", "url": "https://www.investing.com/news/insider-trading-news/mirum-pharmaceuticals-ceo-christopher-peetz-sells-24-million-in-stock-93CH-4782610", "source_name": "Investing.com", "published_at": "2026-07-08T21:11:18", "published_display": "08 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals (MIRM) CFO sells 5,000 shares under 10b5-1 plan", "summary": "Mirum Pharmaceuticals' Chief Financial Officer, Eric Bjerkholt, sold 5,000 shares of common stock on July 6, 2026, through open-market transactions under a pre-arranged Rule 10b5-1 plan. The sales occurred at prices ranging from approximately $121.13 to $124.94 per share. Followi", "url": "https://www.stocktitan.net/sec-filings/MIRM/form-4-mirum-pharmaceuticals-inc-insider-trading-activity-083fcefccdb0.html", "source_name": "Stock Titan", "published_at": "2026-07-08T21:11:18", "published_display": "08 Jul 2026 21:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts Mirum Pharmaceuticals Price Target to $148 From $142, Maintains Outperform Rating", "summary": "RBC Capital has increased its price target for Mirum Pharmaceuticals (MIRM) to $148 from $142, while maintaining an Outperform rating on the stock. This adjustment reflects continued analyst confidence in the biopharmaceutical company, which focuses on treatments for rare liver d", "url": "https://www.marketscreener.com/news/rbc-capital-adjusts-mirum-pharmaceuticals-price-target-to-148-from-142-maintains-outperform-ratin-ce7f5ed8d981f425", "source_name": "marketscreener.com", "published_at": "2026-07-07T12:41:55", "published_display": "07 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eric Bjerkholt reports sale of 5,000 MIRM shares (MIRM)", "summary": "Eric Bjerkholt has reported the sale of 5,000 shares of Mirum Pharmaceuticals (MIRM) common stock on June 8, 2026, with a reported value of $469,073.00. This transaction was disclosed via a Form 144 filing, which is a routine notice for proposed sales of restricted securities. Th", "url": "https://www.stocktitan.net/sec-filings/MIRM/144-mirum-pharmaceuticals-inc-sec-filing-d1f17652102b.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:39:57", "published_display": "06 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Christopher Peetz plans 20,000-share sale (NASDAQ: MIRM)", "summary": "Christopher Peetz has filed a Form 144 indicating a proposed sale of 20,000 shares of Mirum Pharmaceuticals (NASDAQ: MIRM) common stock, which will be executed via a stock option exercise on July 6, 2026. The filing also reports a previous sale of 30,000 shares on June 1, 2026. T", "url": "https://www.stocktitan.net/sec-filings/MIRM/144-mirum-pharmaceuticals-inc-sec-filing-f6ee52aa9edf.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:39:57", "published_display": "06 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Priority Review For Zilurgisertib Could Be A Game Changer For Mirum Pharmaceuticals (MIRM)", "summary": "Mirum Pharmaceuticals (MIRM) has received FDA priority review for zilurgisertib, a drug for fibrodysplasia ossificans progressiva, with a decision expected in late September 2026. This accelerated review and positive phase II results could significantly expand Mirum's rare diseas", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/fda-priority-review-for-zilurgisertib-could-be-a-game-change", "source_name": "Simply Wall Street", "published_at": "2026-07-06T18:10:58", "published_display": "06 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Mirum Pharmaceuticals, Inc. \u2013 NASDAQ:MIRM", "summary": "This article provides financial information for Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) on TradingView. It focuses on the company's enterprise value to EBIT forward metric. The content highlights the stock's market data and available financial tools on the platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-MIRM/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T05:39:57", "published_display": "05 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "J.P. Morgan Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $125", "summary": "J.P. Morgan has reiterated its Buy rating for Mirum Pharmaceuticals (MIRM.US) and increased its price target to $125. This indicates a continued positive outlook from the financial institution regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72406219/jp-morgan-maintains-mirum-pharmaceuticals-mirmus-with-buy-rating-raises", "source_name": "Moomoo", "published_at": "2026-07-03T16:39:13", "published_display": "03 Jul 2026 16:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals SVP sells $326,520 in common stock", "summary": "Jolanda Howe, Senior Vice President at Mirum Pharmaceuticals, sold 2,721 shares of the company's common stock for $326,520, with shares trading at $120.0 each. This sale occurred while the stock was near its 52-week high after a significant 156% gain over the past year, and was e", "url": "https://www.investing.com/news/insider-trading-news/mirum-pharmaceuticals-svp-sells-326520-in-common-stock-93CH-4774535", "source_name": "Investing.com", "published_at": "2026-07-03T05:09:47", "published_display": "03 Jul 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRM - Mirum Pharmaceuticals Inc Latest SEC Filings", "summary": "This article provides the latest SEC filing information for Mirum Pharmaceuticals Inc. (MIRM), offering a comprehensive overview of its financial performance, key valuation metrics, and stock market statistics. It details various financial ratios, insider and institutional owners", "url": "https://finviz.com/stock?t=MIRM&ty=lf&ta=0&p=w&page=17", "source_name": "Finviz", "published_at": "2026-07-03T03:40:42", "published_display": "03 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Jolanda Howe Sells Shares of Mirum Pharmaceuticals Inc (MIRM)", "summary": "Jolanda Howe, Senior Vice President, Global Controller at Mirum Pharmaceuticals Inc, sold 2,721 shares of the company on July 1, 2026, reducing her holdings to 3,114 shares. This transaction is part of a pattern of 39 insider sells against only 1 insider buy for MIRM over the las", "url": "https://www.gurufocus.com/news/8943939/insider-sell-jolanda-howe-sells-shares-of-mirum-pharmaceuticals-inc-mirm", "source_name": "GuruFocus", "published_at": "2026-07-03T00:40:42", "published_display": "03 Jul 2026 00:40", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals (MIRM) SVP Howe sells 2,721 shares under 10b5-1 plan", "summary": "Mirum Pharmaceuticals' SVP and global controller, Jolanda Howe, sold 2,721 shares of common stock at $120.00 per share in an open-market transaction. This sale, totaling $326,520, was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 18, 2026. Following the ", "url": "https://www.stocktitan.net/sec-filings/MIRM/form-4-mirum-pharmaceuticals-inc-insider-trading-activity-e4246a0bc953.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:40:42", "published_display": "02 Jul 2026 21:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals (MIRM) Rallies On Trial News As Its Valuation Story Gets Harder To Ignore", "summary": "Mirum Pharmaceuticals (MIRM) shares rallied 5.5% after positive phase II data and an FDA priority review for zilurgisertib, impacting its market value which now stands at US$7.3 billion. The stock has seen a strong uplift with a 25.05% return in 30 days and 54.30% year-to-date, p", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-rallies-on-trial-news-as-its-valu", "source_name": "Simply Wall Street", "published_at": "2026-07-02T17:40:42", "published_display": "02 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals stock hits all-time high at 125.41 USD", "summary": "Mirum Pharmaceuticals' stock reached an all-time high of $125.41, bringing its market capitalization to $7.6 billion, despite an InvestingPro analysis suggesting it might be overvalued. The company has seen a 147.06% increase over the last year and strong revenue growth of 50%. R", "url": "https://www.investing.com/news/company-news/mirum-pharmaceuticals-stock-hits-alltime-high-at-12541-usd-93CH-4773378", "source_name": "Investing.com", "published_at": "2026-07-02T14:40:42", "published_display": "02 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals stock hits all-time high at 125.41 USD By Investing.com", "summary": "Mirum Pharmaceuticals' stock reached an all-time high of $125.41, marking a 147.06% increase over the past year and bringing its market capitalization to $7.6 billion. Despite this, InvestingPro analysis suggests the stock might be overvalued relative to its Fair Value. The compa", "url": "https://ca.investing.com/news/stock-market-news/mirum-pharmaceuticals-stock-hits-alltime-high-at-12541-usd-93CH-4718499", "source_name": "Investing.com Canada", "published_at": "2026-07-02T14:39:57", "published_display": "02 Jul 2026 14:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Mirum Pharmaceuticals (MIRM) Could Change Following Priority FDA Review Of FOP Drug Zilurgisertib", "summary": "Mirum Pharmaceuticals recently reported positive phase II results for zilurgisertib in fibrodysplasia ossificans progressiva (FOP) and received FDA priority review. This development could reshape the investment narrative for Mirum, moving it beyond its reliance on Livmarli and st", "url": "https://sg.finance.yahoo.com/news/bull-case-mirum-pharmaceuticals-mirm-091455002.html", "source_name": "Market source", "published_at": "2026-07-02T09:14:57", "published_display": "02 Jul 2026 09:14", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 MIRUM PHARMACEUTICALS For: 1 July By Investing.com", "summary": "This article from Investing.com reports the filing of Form 144 for MIRUM PHARMACEUTICALS on July 1st. It provides the headline and mentions the stock symbol MIRM, along with a slight percentage increase. The article is very short and largely surrounded by extensive financial mark", "url": "https://ca.investing.com/news/stock-market-news/form-144-mirum-pharmaceuticals-for-1-july-93CH-4717208", "source_name": "Investing.com Canada", "published_at": "2026-07-02T03:39:02", "published_display": "02 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "2,721 performance shares proposed; Jolanda Howe sold 2,594 (MIRM)", "summary": "A Form 144 filing by Morgan Stanley Smith Barney LLC Executive Financial Services discloses a proposed resale of 2,721 performance shares of Mirum Pharmaceuticals, Inc. (MIRM) dated March 15, 2026. The filing also reports that Jolanda Marie Howe previously sold 2,594 common share", "url": "https://www.stocktitan.net/sec-filings/MIRM/144-mirum-pharmaceuticals-inc-sec-filing-47c6dfd85891.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:39:01", "published_display": "01 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Mirum Pharmaceuticals, Inc. \u2013 NASDAQ:MIRM", "summary": "This page from TradingView provides financial information for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), specifically focusing on its forward price-to-sales ratio. The content appears to be a financial data point within a larger platform, showing the company's value for a specifi", "url": "https://www.tradingview.com/symbols/NASDAQ-MIRM/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T19:44:25", "published_display": "01 Jul 2026 19:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals Stock Surges 25%, With A 9-Day Winning Spree", "summary": "Mirum Pharmaceuticals (MIRM) recently experienced a 9-day winning streak, with its stock surging 25% and its market cap increasing by about $1.4 billion to $7.3 billion. While the company demonstrates strong operating performance, its current valuation is considered very high, ma", "url": "https://www.trefis.com/stock/mirm/articles/604921/mirum-pharmaceuticals-stock-surges-25-with-a-9-day-winning-spree/2026-06-29", "source_name": "Trefis", "published_at": "2026-06-29T14:40:53", "published_display": "29 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Mirum Pharmaceuticals, Inc. \u2013 NASDAQ:MIRM", "summary": "This article provides financial information for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), focusing on its forward price-to-book ratio. It appears to be a stub or an entry from a financial data platform, indicating the company's financials, news, community, technicals, and foreca", "url": "https://www.tradingview.com/symbols/NASDAQ-MIRM/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T14:40:53", "published_display": "29 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOb1FGX19JSm5TLTFnTUV6eHF4Q0tDZ1pWUzRhM0tNeGtLWTJRTXpQQVFSMWNjWERlNzk0VUFEU2N0Slgwb21pcTM3dENzVm9iTVUtaWVEQjZxNlJnR3dEX2hXMnM3V3I4WjVDdXJ3ams0VWxDX2lzTlRZd3U1dVJpXzA0VlVwa19UOWd3QWlsbTRQUHdCNkxYOGhwc2RfY3dfVHJQVjlvUG0?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "9-Day Rally Sends Mirum Pharmaceuticals Stock Up 25%", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOVk52elB6dHBfcnFxd3loTDdQZU12NjhfWXU0QTFKX1NDN19xMDhqRFNpSlFETDlVZ29QV3gyM29aZDFDQ0hWODJWNHk0NkYtb2RrTFdoV0hPTHo5eDVNa2xtWG83eDNpcjY1M0VXZXhXYW8wUHhjZFRfZUFrRnZGM2Q5VTRmUXVXTlhPSVZuM21rZUY5eWg3eDRZRGFiRmJiam1UY213RzhYVG0zaHdub3lDckRIV1lqYjZlMjE5cw?oc=5", "source_name": "Trefis", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals Stock Surges 18%, With A 8-Day Winning Spree", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNT3VTeTRnMjRKQlc0S3FMMm5RcjJLaGFocFpVSU1WYjNtOEdld3l1ZTNEczRzN3lqY0FKMkVFN1JqOUFBNFNFWmgzcFcyc2p6clJZdVNLaVUyM3ZMeVQ3MWI1RC1nWnNMQWJsUjFGSG5hM2ZJb2JJcGY5OW1TRTlKUElucmtNRlU4WDRXbUxxSU5Cb09DWnFLMnRfZVFWTXY1NUdOQURrYjhMNW9yaFVLOHI3UWdEaldCRmFpamxicnVLaUE?oc=5", "source_name": "Trefis", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPS0thTmZBX2I1YVJ4WGx5TGxscC0zaHZHR3ZOeW5QUlduZU5Wd0pjelUxQVlZZ2FhcEgxRnhOQk9SWGFmMVBOUnZZdjM2NlJWbTFBNUN3UWhLTm5Vb3hJd3NaaEV1bURNam9CUDVSbG52TTNpRVliMzR6VHZRbVFqY1ladktiLXZhcjJVUnVCR2VUTzAzTXhmUUdlSUpJV04wUXc?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQbi1RTUhFQWZaaWJBcHlxbFpIcDlLdkEwRWpnRzVVbTY5Q2JxNHRKZTV4S0U4b0dabzR6d1BMRXhfSnNLWjVWMXU5UVc0cXpjVWozdVU4aDlxZnpjWlRaSGtNSmVBOXVMai1CNFU0N1Z2bi1uRVhLdmtxREEzeURZLXFYTWpZTlhhWXFLcGRoSVJ6VUFSM2RfeHhGV21BVXl4SlE?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum\u2019s VISTAS Success And What It Could Mean For MIRM Shareholders", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals: A Rare Disease Platform Becoming Bigger Than Its First Franchise", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQTDYteEV5ZDUwTHNDUk1GQkdENzdDNFVGLXdncDlCUUxGVXFFUGJzQS1mWjY4T2dRMTRPM0l5MEdKZHFCYkZvVkV2d1A2aEFpUlFobkhnMHB6TGxUZ19kV0lYZFlvakNGOFR3c3I0bTE5LTNjbUtkSWQ2SjItMXBucnNBSThCa24tanZ6aVRYd3lSLTFOcGZlX19ST1Q5TkVmdFh2ejA1NWhjbkM0UHFjbVA1czZNc28xZGN0aV9DZzZ4WWFyT0RaRGxxSQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals\u2019 $600M notes with 2029 exchange and stock hedge unwinds", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPc0dxLTFwaWFabHZHdzhYNWpUTEstdVVnUGR2RzBxU1FpWk5yaTBOVlRTa0JUWHpFaFEtc0lCY0NvUzFiQ05mLXpzMFNGOVd4ZHczRzNlRVNZQnZlTzl2cXZYR1FZVGdfekJfd01qX01BeVdZNV95c2FPbUppaWE3dGZKRmZYRWJpeEVjVkJSQ3FDNnpRaGsxZDR6cmU5QTNDcDNjVXRRNDVxdEx2dWV2ZVhfOG5MaGhqQnR4UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals (MIRM) Posts Huge US$790 Million Loss Challenging Bullish Profitability Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q1 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPQkJLYTFBQkc1Ni1kaGFnREhRRTlhTlJ1OWJYS191cWpXbVU1elg3Yi01V1hkUDFZR01Xc2xzRHJBZmh3OXFVQnRmY3VnM0dZX2t4bEtwTXJVSzV6T0pnY1FtcDdJNm9EMllDYW5LUkZPLVpWY3ZsZFlmQ3VDWFFYbV9oY3RpdnJ0alhreGZqd2ZvdFVz?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQa3lXVkJkS3pjeV9tLVZ2aWlSN1FjVmxiVEFjZUtnWVdURE5Fc1NzRDhzbmRtRnBOQkFUQnEwSTc5UmE3M1RabXg1eWlHUVlPdkJ5YXZxanFvVzJ1SkktUW5UM1RJU0xTZEVzNGRtdkVRNnlTOWo2bzVJWXFmYkNBc0tOXzJVNm84eE91ZUZHVkZYME1aUm93RnFYY0psYWhyb29vcDVWVQ?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BlackRock (NASDAQ: MIRM) Holds 3.47M Shares, 5.7% Stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQcnJkUDl4QjE0MjVJLXNpZVJ2Mlp3bTllQ05RVnNBM0lib0VsOVZBREVmVWNWOXdTSW1xb1ZfaFVZak5BZTFrRTJrdWtvVFRrRlFheU4zaWNNZFF6ZC13WFd0aTIxMEpmbW10M2NmajA0d1E4WXF6dFFGdjV3OUI0Smc4Q3RFRzJScDZGQllZTHYwNXpndDB3cWpwOHhaLTNFd1Q2NTdYcTFubEdXem1od3ZCSWZlSlkxMHQ0blRCZlZJRlg0eDhGdjFvQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals\u2019 Stock Surged Over 120% in One Year and May Continue to Climb", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPZlBsbUJla2FvQ0F0V0wySHNwSkNpYlgwWlZlSDdrMFgwWUc3ajdFMWFRWmNFbkN2cE1QUjlSOXVDR1Y1cktnS25PdGxTTEoxb2RKcUpNLUFzSTRJSzZFVXI1dk9aa05TdFlzVXUzMWV3dHF5VlljSGxWUTA5N3dHTnViY3NxMFBsLS1kRmxoejJNQUVZbmZIT3ZJakpvbE9sWndHNmVQd25FZkhnZHY2ZmxvZ0s?oc=5", "source_name": "NAI500", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After Its Strong Multi\u2011Year Share Price Run?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPejd3Y3J5eDdOMFVaRE42cFd2T3hHTmJZSVk2TFRNZXNreEp1T3BST3I1Z3Q5UUNDVkwwSk5HQzV6NndfY1Fsa25GQXgtNzM5QktmenNwd0xlYTlBWXIwa3RWZHB5aExJWTZfQnRISjQzNURTR0pSc09zVFFhbWs2bDl6anMyT2tNel84WHZpZ3JaVGNZNy1WSktqeDJxV19YTXFXUW0tOA?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals (MIRM) Moves 5.1% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQelZ0YW41dGZZUU43SmI2ZVdnRm5jeWJoQWNBd1VKd2dtRFpXNHE2SnNDMXJGeTZzU1hxVWlIUFd2UDRONUk0dS02dUt3cHpITzU2VC1nbHhOaXhPZDJVeENucGZBYUk0bUhjc0QySWhtSHgtZ2tWNXg5b1M5UHlzcklwemtGRGtzWXlJYkU0cFdRVjJ4aFdYVTNFT2pvQjBy?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After Its Strong Multi Year Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNMlVMWlBQTmZ4SzQ4TnNIQnVQQjI2QmJXblNuWnZxVndTekhGR0xWc2VaWFFoRFNhbm5MdTluTGFHcWFlUUxWMGdnS01TMmdfWW50SkNVUkcyNGZJcTZ0M2NPbkVUWWdkRjZWOXFWcy1lMnpUdUpPVDZKbkw3MVNrQllxaDg2cjRQM0N0NjFpM0d0YXMwQ1E0?oc=5", "source_name": "Finviz", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals Completes $268.6 Million Acquisition of Bluejay Therapeutics to Strengthen Rare Disease Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPblRuVUR0OUJER1RoSy1QN1hQSUxjaEJDVjB6NTNHb3JZcXBSQWhfUUpfREpEb1BSRDFXbl9Ib2ROV2l4aWlleXlVcjRBVUZLZGd4ZlprVGxwOEsxMWs4Wm16RjJlOGUyNDdwVlp1SEppUEJfM3JFWUNJMERsTThuZGp3ZjJmaEJyMjVhWmtHdzVSdi1vcUZSajdTcFlnZUFOSkJGeU9fR0dCVWhMWWZrcHFGcWVJcVQtUTR4VFRObndMLTNRRVg1VjhhRERCeHNpQXEwYS1ldw?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxNLWtpdThxLWgwdDZhUXl5S1BPbXlERU9jc1psaFZYT05qcVpzX1FaQThrS2x3SmtCLXJiV0R5dGVLeVRkMlhBTW9VcDl5ZVZFcWZFVkZoNlo0dkVHR24zUnVZSkZMT3F2RzhyZGxFXy03d2l4UEx2akdJQnlSZHd0aTJ2Z0p1VUV2LXFtTFQ3ZTdoTkRPS0tYS0U5LXZQTmdQV1ZKTXpXclRjWTl3MWtZT2wxamxvN3VaX0RCYWtUNkpFNmhBZ1lHSGtPWGR1VEZRQ2VaUEZBSUx6bkd5X3hjMWVURk9sYjF3WFo0TURqU3VEZ1FaRG9BX0ZFNmQ?oc=5", "source_name": "Business Wire", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 103, "total_relevant": 63, "sentiment_summary": {"positive": 16, "negative": 8, "neutral": 39, "score": 53, "total": 63, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 22.35, "count": 40}, {"event": "earnings", "label": "Earnings", "weight": 7.56, "count": 16}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 118.86, "latest_week": "2026-07-17", "one_week_move": -2.7, "four_week_move": 10.9, "twelve_week_move": 29.9, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.160213, "market_dynamics_buy_signal": false, "relative_strength": 24.680117, "fair_value_gap": 124.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 57.8569, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.7% over one week, +10.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "Stock Titan", "count": 9}, {"label": "simplywall.st", "count": 6}, {"label": "TradingView", "count": 6}, {"label": "Moomoo", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "Trefis", "count": 3}, {"label": "Business Wire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 40}, {"label": "Earnings", "count": 16}, {"label": "Analyst action", "count": 3}, {"label": "Deals and strategy", "count": 3}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-2.7% over one week, +10.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Mirum Pharmaceuticals (MIRM) Stock Looks Fully Valued On Current Sales Expectations"}], "updated_at": "2026-07-23T07:33:04.906932+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}